title: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
abstract: BACKGROUND
  We compared telavancin with vancomycin for the treatment of complicated skin and skin-structure infections (cSSSI) caused by Gram-positive bacteria.
  
  
  METHODS
  This was a retrospective analysis of clinical and microbiologic efficacy assessed at test-of-cure (7 to 14 days after completing therapy) in 194 patients from 2 randomized, double-blind clinical trials comparing telavancin (10 mg/kg intravenous [IV] every 24 hours; n = 101) with vancomycin (1 g IV every 12 hours; n = 93) for the treatment of cSSSI.
  
  
  RESULTS
  Baseline characteristics were similar for both treatment groups. Clinical cure and microbiologic eradication rates demonstrated consistent trends favoring telavancin over vancomycin; however, the differences were not statistically significant. The incidence of adverse events was mostly similar between groups.
  
  
  CONCLUSIONS
  The efficacy of telavancin was at least equivalent to that of vancomycin for the treatment of cSSSI. These data suggest that telavancin may be a useful alternative for treatment of cSSSI caused by S. aureus, particularly MRSA.
authors.affiliation: Department of Surgery, University of California, Irvine School of Medicine, Orange, CA, USA. wilsonse@uci.edu
authors.forename: Samuel E
authors.initials: SE
authors.lastname: Wilson
authors.forename: William
authors.initials: W
authors.lastname: O'Riordan
authors.forename: Alan
authors.initials: A
authors.lastname: Hopkins
authors.forename: H David
authors.initials: HD
authors.lastname: Friedland
authors.forename: Steven L
authors.initials: SL
authors.lastname: Barriere
authors.forename: Michael M
authors.initials: MM
authors.lastname: Kitt
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077427:Lipoglycopeptides; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus; D008875:Middle Aged; D012189:Retrospective Studies; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy*; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D014640:Vancomycin; C487637:telavancin